{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:14:06Z","timestamp":1793042046706,"version":"4.5.0"},"reference-count":104,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Grade 2 and most grade 3 isocitrate dehydrogenase (IDH) mutant diffuse gliomas are slow growing tumors, for which however no curative treatment is available. Although surgery as extensive as possible improves outcome, for virtually all patients at some point in time further treatment is necessary. Treatment with radiotherapy and chemotherapy is very effective in controlling tumor growth in most patients, but has side effects. Therefore, in many patients these are postponed and a postoperative \u201cwatch-and-wait\u201d observational strategy is followed. With the approval of IDH inhibitors, another effective strategy has emerged allowing further delay of treatment with radiotherapy and chemotherapy. This underscores the need for guidance how to best follow these patients during their subsequent phases of treatment, but most guidelines give only minimal recommendations for follow-up. Follow-up should not be limited to imaging only, but should also routinely assess seizures and cognition of patients. Follow-up intervals should be based on the risk of progression, allowing longer intervals for patients with oligodendroglioma, for more definitively treated patients and for patients with longer lasting disease stabilization. Evidence justifying a more intensive follow-up of patients on IDH inhibitors than for patients on a \u201cwatch-and-wait\u201d strategy is lacking. Assessing a growth trajectory over time and routine two-dimensional or three-dimensional tumor assessment will allow identification of early changes in growth rate. This manuscript provides guidance for optimal follow-up of these patients with perspectives from all involved disciplines, as indeed the follow-up of these patients needs to be truly multidisciplinary, at every step along the pathway of these patients.<\/jats:p>","DOI":"10.1093\/nop\/npag032","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T02:13:25Z","timestamp":1776046405000},"page":"854-866","source":"Crossref","is-referenced-by-count":1,"title":["Multidisciplinary recommendations for routine follow-up of isocitrate dehydrogenase\u2011mutant glioma in 2026: Adapting clinical practice to the molecular era"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4317-5770","authenticated-orcid":false,"given":"Mary Jane","family":"Lim-Fat","sequence":"first","affiliation":[{"name":"Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre , Toronto,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1384-1709","authenticated-orcid":false,"given":"Amelie","family":"Darlix","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Institut R\u00e9gional du Cancer de Montpellier, University of Montpellier , Montpellier,","place":["France"]},{"name":"Institute of Functional Genomics, University of Montpellier, CNRS, INSERM , Montpellier,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1083-8232","authenticated-orcid":false,"given":"Bogdana","family":"Suchorska","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Heidelberg University Hospital , Heidelberg,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4137-9016","authenticated-orcid":false,"given":"Antonella","family":"Castellano","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Vita-Salute San Raffaele University , Milan,","place":["Italy"]},{"name":"Neuroradiology Unit and CERMAC, IRCCS Ospedale San Raffaele , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1239-1603","authenticated-orcid":false,"given":"Giuseppe","family":"Minniti","sequence":"additional","affiliation":[{"name":"Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome , Rome,","place":["Italy"]},{"name":"IRCCS Neuromed , Pozzilli,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2690-5022","authenticated-orcid":false,"given":"Maarten","family":"Wijnenga","sequence":"additional","affiliation":[{"name":"Brain Tumor Center at Erasmus MC Cancer Institute , Rotterdam,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4423-7256","authenticated-orcid":false,"given":"Susan C","family":"Short","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Leeds Institute of Medical Research, St James\u2019s Hospital , Leeds,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5710-5127","authenticated-orcid":false,"given":"Martin J","family":"van den Bent","sequence":"additional","affiliation":[{"name":"Brain Tumor Center at Erasmus MC Cancer Institute , Rotterdam,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"2026091601515369900_npag032-B1","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"2026091601515369900_npag032-B2","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/S0140-6736(23)01054-1","article-title":"Primary brain tumours in adults","volume":"402","author":"van den Bent","year":"2023","journal-title":"Lancet"},{"key":"2026091601515369900_npag032-B3","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2026091601515369900_npag032-B4","article-title":"Central nervous system tumors in adolescents and young adults: a Society for Neuro-Oncology consensus review on diagnosis, management, and future directions","author":"Lim-Fat","year":"2024","journal-title":"Neuro Oncol"},{"key":"2026091601515369900_npag032-B5","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S1470-2045(25)00534-0","article-title":"A prognostic classification system for extent of resection in IDH-mutant grade 2 glioma: an international, multicentre, retrospective cohort study with external validation by the RANO resect group","volume":"26","author":"Karschnia","year":"2025","journal-title":"Lancet Oncol"},{"key":"2026091601515369900_npag032-B6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/neuonc\/nox176","article-title":"The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis","volume":"20","author":"Wijnenga","year":"2018","journal-title":"Neuro Oncol"},{"key":"2026091601515369900_npag032-B7","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1200\/JCO.23.02195","article-title":"Multidisciplinary management of isocitrate dehydrogenase\u2013mutated gliomas in a contemporary molecularly defined era","volume":"42","author":"Kotecha","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026091601515369900_npag032-B8","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1080\/14656566.2025.2516617","article-title":"Low-grade IDH-mutant gliomas: from standard post-surgical treatments to novel IDH inhibitors","volume":"26","author":"Rud\u00e0","year":"2025","journal-title":"Expert Opin Pharmacother"},{"key":"2026091601515369900_npag032-B9","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMoa2304194","article-title":"Vorasidenib in IDH1- or IDH2-mutant low-grade glioma","volume":"389","author":"Mellinghoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026091601515369900_npag032-B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00614-X","article-title":"Concurrent and adjuvant temozolomide for 1p\/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 study","volume":"2","author":"van den Bent","year":"2026","journal-title":"Lancet Oncol"},{"key":"2026091601515369900_npag032-B11","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1200\/JCO.21.02036","article-title":"Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO guideline","volume":"40","author":"Mohile","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026091601515369900_npag032-B12","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1200\/JCO.21.02543","article-title":"Joint final report of EORTC 26951 and RTOG 9402: phase III trials with procarbazine, lomustine, and vincristine chemotherapy for anaplastic oligodendroglial tumors","volume":"40","author":"Lassman","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026091601515369900_npag032-B13","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1200\/JCO-25-00250","article-title":"Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO guideline rapid recommendation update","volume":"43","author":"Blakeley","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026091601515369900_npag032-B14","author":"National Comprehensive Cancer Network","year":"2025"},{"key":"2026091601515369900_npag032-B15","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.3171\/2022.1.JNS212514","article-title":"The impact of resection in IDH-mutant WHO grade 2 gliomas: a retrospective population-based parallel cohort study","volume":"137","author":"Jakola","year":"2022","journal-title":"J Neurosurg"},{"key":"2026091601515369900_npag032-B16","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1200\/JCO.21.02929","article-title":"Interactive effects of molecular, therapeutic, and patient factors on outcome of diffuse low-grade glioma","volume":"41","author":"Hervey-Jumper","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026091601515369900_npag032-B17","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1093\/annonc\/mdx230","article-title":"Surgical resection versus watchful waiting in low-grade gliomas","volume":"28","author":"Jakola","year":"2017","journal-title":"Ann Oncol"},{"key":"2026091601515369900_npag032-B18","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s11060-016-2201-2","article-title":"Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1\/2 mutation without the 1p\/19q co-deletion","volume":"129","author":"Kawaguchi","year":"2016","journal-title":"J Neurooncol"},{"key":"2026091601515369900_npag032-B19","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/neuonc\/noaa225","article-title":"Association of supratotal resection with progression-free survival, malignant transformation, and overall survival in lower-grade gliomas","volume":"23","author":"Rossi","year":"2021","journal-title":"Neuro Oncol"},{"key":"2026091601515369900_npag032-B20","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.clineuro.2016.09.013","article-title":"Repeat surgery for recurrent low-grade gliomas should be standard of care","volume":"151","author":"Uppstrom","year":"2016","journal-title":"Clin Neurol Neurosurg"},{"key":"2026091601515369900_npag032-B21","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/S1470-2045(25)00592-3","article-title":"Increased extent of neurosurgical resection in IDH-mutated glioma: issues for translation to standard practice","volume":"26","author":"Back","year":"2025","journal-title":"Lancet Oncol"},{"key":"2026091601515369900_npag032-B22","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1038\/s41416-020-0814-x","article-title":"IDH mutation in glioma: molecular mechanisms and potential therapeutic targets","volume":"122","author":"Han","year":"2020","journal-title":"Br J Cancer"},{"key":"2026091601515369900_npag032-B23","doi-asserted-by":"publisher","first-page":"189102","DOI":"10.1016\/j.bbcan.2024.189102","article-title":"Molecular biology and novel therapeutics for IDH mutant gliomas: the new era of IDH inhibitors","volume":"1879","author":"Kitagawa","year":"2024","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"2026091601515369900_npag032-B24","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/s41586-023-06615-2","article-title":"Ultra-fast deep-learned CNS tumour classification during surgery","volume":"622","author":"Vermeulen","year":"2023","journal-title":"Nature"},{"key":"2026091601515369900_npag032-B25","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/s41591-025-03562-5","article-title":"Prospective, multicenter validation of a platform for rapid molecular profiling of central nervous system tumors","volume":"31","author":"Patel","year":"2025","journal-title":"Nat Med"},{"key":"2026091601515369900_npag032-B26","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1093\/neuonc\/nov095","article-title":"Consensus recommendations for a standardized brain tumor imaging protocol in clinical trials","volume":"17","author":"Ellingson","year":"2015","journal-title":"Neuro Oncol"},{"key":"2026091601515369900_npag032-B27","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1093\/neuonc\/noaa105","article-title":"Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment","volume":"22","author":"Huang","year":"2020","journal-title":"Neuro Oncol"},{"key":"2026091601515369900_npag032-B28","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ejrad.2008.06.013","article-title":"Volumes and growth rates of untreated adult low-grade gliomas indicate risk of early malignant transformation","volume":"72","author":"Rees","year":"2009","journal-title":"Eur J Radiol"},{"key":"2026091601515369900_npag032-B29","doi-asserted-by":"publisher","first-page":"E4","DOI":"10.3171\/2023.11.FOCUS23648","article-title":"Radiographic growth rate as a predictor of aggressiveness of diffuse gliomas without 1p19q codeletion","volume":"56","author":"Leclerc","year":"2024","journal-title":"Neurosurg Focus"},{"key":"2026091601515369900_npag032-B30","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1093\/neuonc\/noaf173","article-title":"The use of minor response, volumetric assessment and growth rate kinetics as endpoints in grade 1-3 glioma clinical trials: a RANO perspective","volume":"27","author":"van den Bent","year":"2025","journal-title":"Neuro Oncol"},{"key":"2026091601515369900_npag032-B31","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1200\/JCO.23.01059","article-title":"RANO 2.0: update to the response assessment in neuro-oncology criteria for high- and low-grade gliomas in adults","volume":"41","author":"Wen","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026091601515369900_npag032-B32","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1093\/neuonc\/noab256","article-title":"Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: evidence from a phase I trial of ivosidenib","volume":"24","author":"Ellingson","year":"2022","journal-title":"Neuro Oncol"},{"key":"2026091601515369900_npag032-B33","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.1109\/EMBC.2016.7591703","article-title":"Statistical evaluation of manual segmentation of a diffuse low-grade glioma MRI dataset","volume":"2016","author":"Ben Abdallah","year":"2016","journal-title":"Annu Int Conf IEEE Eng Med Biol Soc"},{"key":"2026091601515369900_npag032-B34","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s11060-016-2312-9","article-title":"Intra-rater variability in low-grade glioma segmentation","volume":"131","author":"B\u00f8","year":"2017","journal-title":"J Neurooncol"},{"key":"2026091601515369900_npag032-B35","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/S1470-2045(19)30098-1","article-title":"Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study","volume":"20","author":"Kickingereder","year":"2019","journal-title":"Lancet Oncol"},{"key":"2026091601515369900_npag032-B36","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/neuonc\/noac189","article-title":"Artificial intelligence (AI)-based decision support improves reproducibility of tumor response assessment in neuro-oncology: an international multi-reader study","volume":"25","author":"Vollmuth","year":"2023","journal-title":"Neuro Oncol"},{"key":"2026091601515369900_npag032-B37","doi-asserted-by":"publisher","first-page":"vdaf256","DOI":"10.1093\/noajnl\/vdaf256","article-title":"Beyond proof-of-concept: validating robust automated diffuse lower-grade glioma segmentation for clinical applications in longitudinal follow-up","volume":"8","author":"Deverdun","year":"2026","journal-title":"Neurooncol Adv"},{"key":"2026091601515369900_npag032-B38","doi-asserted-by":"publisher","first-page":"97","DOI":"10.5414\/NP301084","article-title":"Reactive gliosis mimicking tumor recurrence\u2014a case series documenting MRI abnormalities and neuropathological correlates","volume":"37","author":"Kearney","year":"2018","journal-title":"Clin Neuropathol"},{"key":"2026091601515369900_npag032-B39","doi-asserted-by":"publisher","first-page":"109674","DOI":"10.1016\/j.radonc.2023.109674","article-title":"Early and late contrast enhancing lesions after photon radiotherapy for IDH mutated grade 2 diffuse glioma","volume":"184","author":"Jaspers","year":"2023","journal-title":"Radiother Oncol"},{"key":"2026091601515369900_npag032-B40","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1093\/neuonc\/noac194","article-title":"Incidence and characteristics of pseudoprogression in IDH-mutant high-grade gliomas: a POLA network study","volume":"25","author":"Seyve","year":"2023","journal-title":"Neuro Oncol"},{"key":"2026091601515369900_npag032-B41","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s00234-020-02621-7","article-title":"Intracranial long-term complications of radiation therapy: an image-based review","volume":"63","author":"Carr","year":"2021","journal-title":"Neuroradiology"},{"key":"2026091601515369900_npag032-B42","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1111\/ene.15873","article-title":"T2-fluid-attenuated inversion recovery (FLAIR) pseudoprogression in patients with anaplastic oligodendrogliomas treated with procarbazine, lomustine and vincristine (PCV) chemotherapy alone","volume":"30","author":"Esparragosa Vazquez","year":"2023","journal-title":"Eur J Neurol"},{"key":"2026091601515369900_npag032-B43","doi-asserted-by":"publisher","first-page":"424","DOI":"10.3390\/cancers13030424","article-title":"Advancements in neuroimaging to unravel biological and molecular features of brain tumors","volume":"13","author":"Sanvito","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026091601515369900_npag032-B44","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s41582-021-00510-y","article-title":"MRI biomarkers in neuro-oncology","volume":"17","author":"Smits","year":"2021","journal-title":"Nat Rev Neurol"},{"key":"2026091601515369900_npag032-B45","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s00330-018-5608-7","article-title":"Imaging prediction of isocitrate dehydrogenase (IDH) mutation in patients with glioma: a systemic review and meta-analysis","volume":"29","author":"Suh","year":"2019","journal-title":"Eur Radiol"},{"key":"2026091601515369900_npag032-B46","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1148\/radiol.2020191832","article-title":"World Health Organization grade II\/III glioma molecular status: prediction by MRI morphologic features and apparent diffusion coefficient","volume":"296","author":"Maynard","year":"2020","journal-title":"Radiology"},{"key":"2026091601515369900_npag032-B47","doi-asserted-by":"publisher","first-page":"16238","DOI":"10.1038\/srep16238","article-title":"IDH mutation status is associated with a distinct hypoxia\/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma","volume":"5","author":"Kickingereder","year":"2015","journal-title":"Sci Rep"},{"key":"2026091601515369900_npag032-B48","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1093\/neuonc\/noy048","article-title":"The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p\/19q-intact lower-grade glioma: a validation study","volume":"20","author":"Broen","year":"2018","journal-title":"Neuro Oncol"},{"key":"2026091601515369900_npag032-B49","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/jmri.22068","article-title":"Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity","volume":"31","author":"Ellingson","year":"2010","journal-title":"J Magn Reson Imaging"},{"key":"2026091601515369900_npag032-B50","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1007\/s00330-015-3934-6","article-title":"Evaluation of low-grade glioma structural changes after chemotherapy using DTI-based histogram analysis and functional diffusion maps","volume":"26","author":"Castellano","year":"2016","journal-title":"Eur Radiol"},{"key":"2026091601515369900_npag032-B51","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1148\/radiol.2471062089","article-title":"Low-grade gliomas: do changes in rCBV measurements at longitudinal perfusion-weighted MR imaging predict malignant transformation?","volume":"247","author":"Danchaivijitr","year":"2008","journal-title":"Radiology"},{"key":"2026091601515369900_npag032-B52","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1007\/s00234-021-02737-4","article-title":"Perfusion imaging with arterial spin labeling (ASL)-MRI predicts malignant progression in low\u2011grade (WHO grade) gliomas","volume":"63","author":"Flies","year":"2021","journal-title":"Neuroradiology"},{"key":"2026091601515369900_npag032-B53","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/nm.2682","article-title":"2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas","volume":"18","author":"Choi","year":"2012","journal-title":"Nat Med"},{"key":"2026091601515369900_npag032-B54","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1093\/neuonc\/noy113","article-title":"2-Hydroxyglutarate MR spectroscopy for prediction of isocitrate dehydrogenase mutant glioma: a systemic review and meta-analysis using individual patient data","volume":"20","author":"Suh","year":"2018","journal-title":"Neuro Oncol"},{"key":"2026091601515369900_npag032-B55","doi-asserted-by":"publisher","first-page":"4030","DOI":"10.1200\/JCO.2016.67.1222","article-title":"Prospective longitudinal analysis of 2-hydroxyglutarate magnetic resonance spectroscopy identifies broad clinical utility for the management of patients with IDH-mutant glioma","volume":"34","author":"Choi","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026091601515369900_npag032-B56","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1212\/WNL.0000000000201137","article-title":"In vivo 2-hydroxyglutarate monitoring with edited MR spectroscopy for the follow-up of IDH-mutant diffuse gliomas: the IDASPE prospective study","volume":"100","author":"Di Stefano","year":"2023","journal-title":"Neurology"},{"key":"2026091601515369900_npag032-B57","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3174\/ajnr.A8413","article-title":"Incorporation of edited MRS into clinical practice may improve care of patients with IDH-mutant glioma","volume":"46","author":"Nichelli","year":"2025","journal-title":"AJNR Am J Neuroradiol"},{"key":"2026091601515369900_npag032-B58","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1007\/s00330-018-5314-5","article-title":"Glioma imaging in Europe: a survey of 220 centres and recommendations for best clinical practice","volume":"28","author":"Thust","year":"2018","journal-title":"Eur Radiol"},{"key":"2026091601515369900_npag032-B59","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/jmri.26645","article-title":"APT-weighted MRI: techniques, current neuro applications, and challenging issues","volume":"50","author":"Zhou","year":"2019","journal-title":"J Magn Reson Imaging"},{"key":"2026091601515369900_npag032-B60","doi-asserted-by":"publisher","first-page":"e4731","DOI":"10.1002\/nbm.4731","article-title":"Applications of chemical exchange saturation transfer magnetic resonance imaging in identifying genetic markers in gliomas","volume":"36","author":"Jiang","year":"2023","journal-title":"NMR Biomed"},{"key":"2026091601515369900_npag032-B61","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1002\/mrm.26820","article-title":"Predicting IDH mutation status in grade II gliomas using amide proton transfer-weighted (APTw) MRI","volume":"78","author":"Jiang","year":"2017","journal-title":"Magn Reson Med"},{"key":"2026091601515369900_npag032-B62","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1016\/S1470-2045(23)00525-9","article-title":"PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group","volume":"25","author":"Albert","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026091601515369900_npag032-B63","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1093\/neuonc\/noad240","article-title":"The potential of amino acid PET imaging for prediction and monitoring of vorasidenib response in IDH-mutant gliomas","volume":"26","author":"Albert","year":"2024","journal-title":"Neuro Oncol"},{"key":"2026091601515369900_npag032-B64","doi-asserted-by":"publisher","first-page":"e242","DOI":"10.1111\/epi.18593","article-title":"Early seizure freedom with [(18)F]fluorodopa positron emission tomography response after isocitrate dehydrogenase inhibition with vorasidenib: first case report","volume":"66","author":"Rud\u00e0","year":"2025","journal-title":"Epilepsia"},{"key":"2026091601515369900_npag032-B65","doi-asserted-by":"publisher","first-page":"e230793","DOI":"10.1148\/radiol.230793","article-title":"Brain tumor imaging without gadolinium-based contrast agents: feasible or fantasy?","volume":"310","author":"Wamelink","year":"2024","journal-title":"Radiology"},{"key":"2026091601515369900_npag032-B66","doi-asserted-by":"publisher","first-page":"4257","DOI":"10.1007\/s00330-024-11333-y","article-title":"How useful is contrast-enhanced MRI in the long-term surveillance of glioma? A multicentre retrospective longitudinal cohort study","volume":"35","author":"Cakmak","year":"2025","journal-title":"Eur Radiol"},{"key":"2026091601515369900_npag032-B67","doi-asserted-by":"publisher","first-page":"7774","DOI":"10.1007\/s00330-025-11646-6","article-title":"Recommendations on the use of gadolinium-based contrast agents in the diagnosis and monitoring of common adult intracranial tumours","volume":"35","author":"Doniselli","year":"2025","journal-title":"Eur Radiol"},{"key":"2026091601515369900_npag032-B68","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1093\/nop\/npae031","article-title":"Life with a lower-grade glioma: how can neuro-oncologists advance its understanding and management?","volume":"11","author":"Darlix","year":"2024","journal-title":"Neurooncol Pract"},{"key":"2026091601515369900_npag032-B69","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1002\/ana.10528","article-title":"Continuous growth of mean tumor diameter in a subset of grade II gliomas","volume":"53","author":"Mandonnet","year":"2003","journal-title":"Ann Neurol"},{"key":"2026091601515369900_npag032-B70","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s10143-009-0229-x","article-title":"Inter- and intrapatients comparison of WHO grade II glioma kinetics before and after surgical resection","volume":"33","author":"Mandonnet","year":"2010","journal-title":"Neurosurg Rev"},{"key":"2026091601515369900_npag032-B71","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1007\/s00701-013-1914-7","article-title":"No growth\u201d on serial MRI scans of a low grade glioma?","volume":"155","author":"Jakola","year":"2013","journal-title":"Acta Neurochir (Wien)"},{"key":"2026091601515369900_npag032-B72","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00701-018-03783-3","article-title":"Radiology reporting of low-grade glioma growth underestimates tumor expansion","volume":"161","author":"Gui","year":"2019","journal-title":"Acta Neurochir (Wien)"},{"key":"2026091601515369900_npag032-B73","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1148\/radiol.100299","article-title":"Comment on parameters of low-grade glioma as predictors","volume":"256","author":"Pallud","year":"2010","journal-title":"Radiology"},{"key":"2026091601515369900_npag032-B74","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s11060-013-1051-4","article-title":"Effects of slice thickness and head rotation when measuring glioma sizes on MRI: in support of volume segmentation versus two largest diameters methods","volume":"112","author":"Schmitt","year":"2013","journal-title":"J Neurooncol"},{"key":"2026091601515369900_npag032-B75","doi-asserted-by":"publisher","first-page":"vdae044","DOI":"10.10903\/noajnl\/vdae044","article-title":"Diffuse low-grade glioma: what is the optimal linear measure to assess tumor growth?","volume":"6","author":"Dos Santos","year":"2024","journal-title":"Neurooncol Adv"},{"key":"2026091601515369900_npag032-B76","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1093\/neuonc\/noaf118","article-title":"Response assessment in neuro-oncology (RANO) 2009\u20132025: broad scope and implementation\u2014a progress report","volume":"27","author":"van den Bent","year":"2025","journal-title":"Neuro Oncol"},{"key":"2026091601515369900_npag032-B77","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1093\/neuonc\/noab275","article-title":"Cognitive preservation following awake mapping-based neurosurgery for low-grade gliomas: a longitudinal, within-patient design study","volume":"24","author":"Lemaitre","year":"2022","journal-title":"Neuro Oncol"},{"key":"2026091601515369900_npag032-B78","doi-asserted-by":"publisher","first-page":"vdae084","DOI":"10.1093\/noajnl\/vdae084","article-title":"Longitudinal assessment of quality of life, neurocognition, and psychopathology in patients with low-grade glioma on first-line temozolomide: a feasibility study","volume":"6","author":"Darlix","year":"2024","journal-title":"Neurooncol Adv"},{"key":"2026091601515369900_npag032-B79","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1093\/neuonc\/noaf172","article-title":"Health-related quality of life and cognitive functioning in survivors of oligodendroglioma: an international cross-sectional investigation","volume":"27","author":"Boele","year":"2025","journal-title":"Neuro Oncol"},{"key":"2026091601515369900_npag032-B80","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1200\/JCO.2002.08.121","article-title":"Prognostic factors for survival in adult patients with cerebral low-grade glioma","volume":"20","author":"Pignatti","year":"2002","journal-title":"J Clin Oncol"},{"key":"2026091601515369900_npag032-B81","first-page":"284","article-title":"Preliminary results of RTOG protocol 9802: a phase Ii study of observation in completely resected adult low grade glioma","volume":"72005","author":"Shaw","journal-title":"Neuro Oncol"},{"key":"2026091601515369900_npag032-B82","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1093\/neuonc\/noae107","article-title":"The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: how should they inform treatment decisions in the era of IDH inhibitors?","volume":"26","author":"van den Bent","year":"2024","journal-title":"Neuro Oncol"},{"key":"2026091601515369900_npag032-B83","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1056\/NEJMoa1500925","article-title":"Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma","volume":"374","author":"Buckner","year":"2016","journal-title":"N Engl J Med"},{"key":"2026091601515369900_npag032-B84","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1200\/JCO.19.02983","article-title":"Comprehensive genomic analysis in NRG oncology\/RTOG 9802: a phase III trial of radiation versus radiation plus procarbazine, lomustine (CCNU), and vincristine in high-risk low-grade glioma","volume":"38","author":"Bell","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026091601515369900_npag032-B85","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0140-6736(05)67070-5","article-title":"Long term results of EORTC study 22845: a randomized trial on the efficacy of early versus delayed radiation therapy of low-grade astrocytoma and oligodendroglioma in the adult","volume":"366","author":"van den Bent","year":"2005","journal-title":"Lancet"},{"key":"2026091601515369900_npag032-B86","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1093\/neuonc\/noaa021","article-title":"Final report from intergroup NCCTG 86-72-51 (alliance): a phase III randomized clinical trial of high-dose versus low-dose radiation for adult low-grade glioma","volume":"22","author":"Breen","year":"2020","journal-title":"Neuro Oncol"},{"key":"2026091601515369900_npag032-B87","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/s0360-3016(96)00352-5","article-title":"A randomized trial on dose-response in radiation therapy of low grade cerebral glioma: European organization for research and treatment of cancer (EORTC) study 2284","volume":"36","author":"Karim","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026091601515369900_npag032-B88","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/S1474-4422(09)70204-2","article-title":"Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up","volume":"8","author":"Douw","year":"2009","journal-title":"Lancet Neurol"},{"key":"2026091601515369900_npag032-B89","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/s0140-6736(02)11398-5","article-title":"Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study","volume":"360","author":"Klein","year":"2002","journal-title":"Lancet"},{"key":"2026091601515369900_npag032-B90","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013047.pub2","article-title":"Long-term neurocognitive and other side effects of radiotherapy, with or without chemotherapy, for glioma","author":"Lawrie","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2026091601515369900_npag032-B91","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s11060-020-03454-3","article-title":"Healthcare utilization and productivity loss in glioma patients and family caregivers: the impact of treatable psychological symptoms","volume":"147","author":"Boele","year":"2020","journal-title":"J Neurooncol"},{"key":"2026091601515369900_npag032-B92","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1200\/JCO.2014.56.9079","article-title":"Health-related quality of life in stable, long-term survivors of low-grade glioma","volume":"33","author":"Boele","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026091601515369900_npag032-B93","doi-asserted-by":"publisher","first-page":"e097810","DOI":"10.1136\/bmjopen-2024-097810","article-title":"APPROACH: analysis of proton versus photon radiotherapy in oligodendroglioma and assessment of cognitive health\u2014study protocol paper for a phase III multicentre, open-label randomised controlled trial","volume":"15","author":"Slevin","year":"2025","journal-title":"BMJ Open"},{"key":"2026091601515369900_npag032-B94","author":"National Comprehensive Cancer Network (NCCN)","year":"2025"},{"key":"2026091601515369900_npag032-B95","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051381","article-title":"Scanxiety among adults with cancer: a scoping review to guide research and interventions","volume":"15","author":"Derry-Vick","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026091601515369900_npag032-B96","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1093\/neuonc\/noac031","article-title":"Surveillance imaging frequency in adult patients with lower-grade (WHO grade 2 and 3) gliomas","volume":"24","author":"Jo","year":"2022","journal-title":"Neuro Oncol"},{"key":"2026091601515369900_npag032-B97","doi-asserted-by":"publisher","first-page":"4565","DOI":"10.1158\/1078-0432.CCR-22-1133","article-title":"Early postoperative treatment versus initial observation in CNS WHO grade 2 and 3 oligodendroglioma: clinical outcomes and DNA methylation patterns","volume":"28","author":"Mair","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026091601515369900_npag032-B98","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s11060-022-04128-y","article-title":"Limited efficacy of temozolomide alone for astrocytoma, IDH-mutant, CNS WHO grades 2 or 3","volume":"160","author":"Weller","year":"2022","journal-title":"J Neurooncol"},{"issue":":","key":"2026091601515369900_npag032-B99","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1093\/neuonc\/now133","article-title":"Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide","volume":"18","author":"Wick","year":"2016","journal-title":"Neuro Oncol"},{"key":"2026091601515369900_npag032-B100","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.3171\/2018.2.JNS172951","article-title":"Early postoperative delineation of residual tumor after low-grade glioma resection by probabilistic quantification of diffusion-weighted imaging","volume":"130","author":"Scherer","year":"2019","journal-title":"J Neurosurg"},{"key":"2026091601515369900_npag032-B101","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1007\/s00330-011-2081-y","article-title":"Early postoperative MRI overestimates residual tumour after resection of gliomas with no or minimal enhancement","volume":"21","author":"Belhawi","year":"2011","journal-title":"Eur Radiol"},{"key":"2026091601515369900_npag032-B102","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.wneu.2016.04.120","article-title":"The value of intraoperative and early postoperative magnetic resonance imaging in low-grade glioma surgery: a retrospective study","volume":"93","author":"Pala","year":"2016","journal-title":"World Neurosurg"},{"key":"2026091601515369900_npag032-B103","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/neuonc\/noz200","article-title":"Survival of diffuse astrocytic glioma, IDH1\/2-wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria","volume":"22","author":"Tesileanu","year":"2020","journal-title":"Neuro Oncol"},{"key":"2026091601515369900_npag032-B104","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1093\/neuonc\/nou153","article-title":"New concepts in the management of diffuse low-grade glioma: proposal of a multistage and individualized therapeutic approach","volume":"17","author":"Duffau","year":"2015","journal-title":"Neuro Oncol"}],"container-title":["Neuro-Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/nop\/advance-article-pdf\/doi\/10.1093\/nop\/npag032\/68030586\/npag032.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nop\/article-pdf\/13\/5\/854\/68030586\/npag032.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nop\/article-pdf\/13\/5\/854\/68030586\/npag032.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:52:00Z","timestamp":1789537920000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/nop\/article\/13\/5\/854\/8651329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":104,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,4,10]]},"published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/nop\/npag032","relation":{},"ISSN":["2054-2577","2054-2585"],"issn-type":[{"value":"2054-2577","type":"print"},{"value":"2054-2585","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,4,10]]}}}